Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Galectin Therapeutics Inc

GALT ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$3.96

▲ +1.80%

Market Cap $399.36M · Vol 81.13K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$399.36M

Small Cap

Div Yield

N/A

EPS Growth

+37.50%

YoY

RSI (14)

50.23

Momentum

Beta

0.38

vs Market

52W High

$7.13

45.44% below

52W Low

$2.03

92.10% above

Volume

81.13K

Avg 118.19K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

46.92%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Galectin Therapeutics Inc (GALT) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does GALT pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+3.13%

+7.61%

+40.18%

+44.00%

YTD

-4.81%

-17.50%

+121.23%

+5.32%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-30,836,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-166.56% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	+37.50%
Outstanding Shares	100.85M

Technical Indicators

50-Day SMA	$3.77
200-Day SMA	$3.36
RSI (14)	50.23
Beta	0.38
52-Week High	$7.13
52-Week Low	$2.03

Volume Today	81.13K
Avg Daily Volume (30D)	118.19K
Relative Volume	0.69x
Volatility (10D)	61.54
Volatility (30D)	72.91
Free Float	46.92%

Analyst Consensus

BUY

Current Price $3.96

Mean Target $11.00

52W Low$2.03 52W High$7.13

Current

Target

$2.03 $7.13

Current Analyst target

+177.78% upside potential · 1 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001S9NYW2

ISINUS3632252025

CountryUSA

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 12, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +0.59% ONC BeOne Medicines AG +4.23% 068270.KS Celltrion, Inc. +1.11% MEDP Medpace Holdings, Inc. +1.94% ABVX Abivax SA -1.51%

Company Profile

Galectin Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing therapies to improve the lives of patients with chronic liver disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company’s lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The Company's additional development programs are in the treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.